ASK-POM9-CS101 | Clinical Research Studies Listing

Recruiting

99 years or below

All

Phase N/A

5 participants needed

1 Location

Brief description of study

This is a study to evaluate AB-1009 (IP under study) in adult patients with late-onset pompe disease (LOPD). LOPD is caused by a genetic mutation resulting in a decrease in the GAA enzyme, resulting in the destruction of muscle tissue. AB-1009, administered as a one-time IV dose, is an gene therapy intended to increase the expression of GAA. Participants will receive AB-1009 and then enter a 5-year long follow up period where they will undergo study procedures to review safety and efficacy.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Medical Research
Age: 99 years or below
Gender: All

TBD

Updated on 19 Feb 2026. Study ID: 25-2083

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

View email

Phone

View phone

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Please provide your preferred way of contact

Other language

By Submitting your information, you agree that your details may be shared with the selected study site and handled in accordance with this Website's Privacy Policy (see link in footer). You may be contacted by email, text message, or phone regarding this study and other research opportunities that may be of interested to you. You can unsubscribe from these communications at any time. Message and data rates may apply.

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center